Meet with Johnson and Johnson Innovation in Asia Pacific: Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment
Opens May 17 2021 06:00 AM (GMT)
Deadline Jun 30 2021 03:59 PM (GMT)
Description

NOTE: This application process was closed on Wednesday, 30 June. However, if you're working in any of the areas below, we'd still be interested to hear from you beyond this date. Please do share a non-confidential deck with us by emailing JJIAP@its.jnj.com and a member of our team will be in touch.


Before you request a one-on-one meeting with our team, we encourage you to join our “Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment” webinar (register here). Please note, this 1-to-1 opportunity is not only limited to Immuno-Oncology – see broader oncology areas below.

Application Process:

  1. Register for the “Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment” webinar (click here).
  2. Review the application criteria below.
  3. Log in or create an account on Survey Monkey Apply.
  4. Fill in the application form and upload a slide deck or one-pager (all information should be non-confidential).
  5. Submit by EOD Wednesday, 30 June 2021 (China Standard Time). 
  6. Applications will be reviewed on a rolling basis and selected companies will receive an email invitation from JJIAP@its.jnj.com.
  7. Once notified, confirm attendance of your one-to-one meeting within 72 hours before the webinar. 

If you come across any issues with the application form, please contact JJIAP@its.jnj.com

Application Criteria: 

During this timeframe, we are seeking innovative solutions which will lead to significant patient benefits in the oncology focus areas below. However, if you are working on a solution in an area not listed below, we encourage you to still consider applying in case we can re-route the request to the relevant team for review.

Hematologic malignancies

  • B-cell malignancies
  • Plasma cell malignancies
  • Myeloid malignancies
  • Amyloidosis
  • T-cell lymphoma/leukemia

Prostate cancer

  • Next gen Androgen inhibition
  • Lineage specific biologic targets
  • Early intervention

CRC Interception

  • Detection
  • Prevention
  • Interception

Immune therapy

  • Directed T cell therapies/co-stimulation
  • Inducible pluripotent stem cells
  • Oncolytic virus and vaccine

Solid tumor targeted therapy

  • Targeted therapies
  • Synthetic Lethality
  • Driver pathway focus 

Oncology Data Science

  • Patient Identification and Stratification 
  • Build Clinical Evidence 
  • Identify New Targets

Meet with Johnson and Johnson Innovation in Asia Pacific: Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment


NOTE: This application process was closed on Wednesday, 30 June. However, if you're working in any of the areas below, we'd still be interested to hear from you beyond this date. Please do share a non-confidential deck with us by emailing JJIAP@its.jnj.com and a member of our team will be in touch.


Before you request a one-on-one meeting with our team, we encourage you to join our “Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment” webinar (register here). Please note, this 1-to-1 opportunity is not only limited to Immuno-Oncology – see broader oncology areas below.

Application Process:

  1. Register for the “Driving Next Generation Immuno-Oncology Innovation for Cancer Treatment” webinar (click here).
  2. Review the application criteria below.
  3. Log in or create an account on Survey Monkey Apply.
  4. Fill in the application form and upload a slide deck or one-pager (all information should be non-confidential).
  5. Submit by EOD Wednesday, 30 June 2021 (China Standard Time). 
  6. Applications will be reviewed on a rolling basis and selected companies will receive an email invitation from JJIAP@its.jnj.com.
  7. Once notified, confirm attendance of your one-to-one meeting within 72 hours before the webinar. 

If you come across any issues with the application form, please contact JJIAP@its.jnj.com

Application Criteria: 

During this timeframe, we are seeking innovative solutions which will lead to significant patient benefits in the oncology focus areas below. However, if you are working on a solution in an area not listed below, we encourage you to still consider applying in case we can re-route the request to the relevant team for review.

Hematologic malignancies

  • B-cell malignancies
  • Plasma cell malignancies
  • Myeloid malignancies
  • Amyloidosis
  • T-cell lymphoma/leukemia

Prostate cancer

  • Next gen Androgen inhibition
  • Lineage specific biologic targets
  • Early intervention

CRC Interception

  • Detection
  • Prevention
  • Interception

Immune therapy

  • Directed T cell therapies/co-stimulation
  • Inducible pluripotent stem cells
  • Oncolytic virus and vaccine

Solid tumor targeted therapy

  • Targeted therapies
  • Synthetic Lethality
  • Driver pathway focus 

Oncology Data Science

  • Patient Identification and Stratification 
  • Build Clinical Evidence 
  • Identify New Targets
Opens
May 17 2021 06:00 AM (GMT)
Deadline
Jun 30 2021 03:59 PM (GMT)